 Sarah Beck
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simian Acquired Immunodeficiency Syndrome | 12 | 2019 | 68 | 2.680 |
Why?
| | Ultraviolet Rays | 8 | 2019 | 366 | 2.040 |
Why?
| | Disinfection | 9 | 2019 | 106 | 2.000 |
Why?
| | Water Purification | 7 | 2019 | 128 | 1.940 |
Why?
| | Simian Immunodeficiency Virus | 11 | 2019 | 70 | 1.830 |
Why?
| | Virus Latency | 5 | 2019 | 80 | 1.180 |
Why?
| | Macaca nemestrina | 7 | 2017 | 28 | 1.090 |
Why?
| | Macaca mulatta | 8 | 2019 | 131 | 0.920 |
Why?
| | Disease Models, Animal | 11 | 2019 | 3542 | 0.850 |
Why?
| | RNA, Viral | 3 | 2016 | 566 | 0.830 |
Why?
| | Virus Replication | 6 | 2019 | 395 | 0.810 |
Why?
| | AIDS Dementia Complex | 3 | 2017 | 50 | 0.760 |
Why?
| | Central Nervous System | 3 | 2018 | 237 | 0.750 |
Why?
| | Water Microbiology | 3 | 2017 | 77 | 0.730 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2019 | 689 | 0.680 |
Why?
| | Germinal Center | 1 | 2019 | 48 | 0.670 |
Why?
| | Levivirus | 2 | 2016 | 11 | 0.660 |
Why?
| | HIV-1 | 3 | 2019 | 768 | 0.630 |
Why?
| | Macrophages | 7 | 2019 | 1261 | 0.600 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2016 | 174 | 0.580 |
Why?
| | Escherichia coli | 3 | 2017 | 722 | 0.550 |
Why?
| | SAIDS Vaccines | 1 | 2016 | 3 | 0.530 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2016 | 3 | 0.530 |
Why?
| | Gene Products, gag | 1 | 2016 | 36 | 0.520 |
Why?
| | Viral Load | 8 | 2019 | 405 | 0.510 |
Why?
| | Microbial Viability | 1 | 2015 | 79 | 0.500 |
Why?
| | DNA Damage | 2 | 2014 | 357 | 0.480 |
Why?
| | B-Lymphocytes | 1 | 2019 | 769 | 0.470 |
Why?
| | Anti-Retroviral Agents | 4 | 2019 | 207 | 0.450 |
Why?
| | HIV Infections | 6 | 2019 | 2469 | 0.440 |
Why?
| | Cognitive Dysfunction | 1 | 2017 | 273 | 0.440 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2019 | 965 | 0.430 |
Why?
| | Disease Susceptibility | 1 | 2015 | 316 | 0.430 |
Why?
| | Adenoviridae | 1 | 2013 | 185 | 0.420 |
Why?
| | Antiviral Agents | 1 | 2017 | 646 | 0.400 |
Why?
| | Osteoma, Osteoid | 1 | 2011 | 4 | 0.390 |
Why?
| | Thoracic Vertebrae | 1 | 2011 | 68 | 0.370 |
Why?
| | Tibia | 1 | 2011 | 166 | 0.340 |
Why?
| | Bone Neoplasms | 1 | 2011 | 194 | 0.330 |
Why?
| | Middle East Respiratory Syndrome Coronavirus | 2 | 2019 | 5 | 0.310 |
Why?
| | Animals | 25 | 2019 | 31761 | 0.280 |
Why?
| | Monkey Diseases | 2 | 2016 | 19 | 0.260 |
Why?
| | Pressure | 3 | 2014 | 218 | 0.240 |
Why?
| | CCR5 Receptor Antagonists | 2 | 2014 | 6 | 0.230 |
Why?
| | Cyclohexanes | 2 | 2014 | 22 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2019 | 332 | 0.210 |
Why?
| | Triazoles | 2 | 2014 | 130 | 0.210 |
Why?
| | Brain | 3 | 2019 | 2369 | 0.190 |
Why?
| | Myeloid Cells | 2 | 2019 | 127 | 0.190 |
Why?
| | Dipeptidyl Peptidase 4 | 2 | 2019 | 10 | 0.180 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2015 | 316 | 0.170 |
Why?
| | Vascularized Composite Allotransplantation | 1 | 2019 | 22 | 0.160 |
Why?
| | Skin Transplantation | 1 | 2019 | 57 | 0.160 |
Why?
| | Bacteroides fragilis | 1 | 2018 | 11 | 0.160 |
Why?
| | Hindlimb | 1 | 2019 | 130 | 0.160 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2018 | 30 | 0.160 |
Why?
| | Th17 Cells | 1 | 2018 | 58 | 0.150 |
Why?
| | Agriculture | 1 | 2019 | 72 | 0.150 |
Why?
| | Equipment Contamination | 1 | 2018 | 54 | 0.150 |
Why?
| | Fiducial Markers | 1 | 2018 | 8 | 0.150 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2018 | 25 | 0.150 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 30 | 0.150 |
Why?
| | Cross Reactions | 1 | 2018 | 117 | 0.150 |
Why?
| | Diastole | 2 | 2015 | 131 | 0.150 |
Why?
| | Potassium Compounds | 1 | 2017 | 8 | 0.140 |
Why?
| | Atrazine | 1 | 2017 | 8 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2018 | 283 | 0.140 |
Why?
| | Sulfates | 1 | 2017 | 43 | 0.140 |
Why?
| | Sunlight | 1 | 2017 | 57 | 0.140 |
Why?
| | Receptors, Virus | 1 | 2016 | 75 | 0.140 |
Why?
| | Meningitis | 1 | 2017 | 74 | 0.140 |
Why?
| | Safety | 1 | 2018 | 297 | 0.130 |
Why?
| | Colitis | 1 | 2018 | 223 | 0.130 |
Why?
| | Encephalitis | 1 | 2017 | 127 | 0.130 |
Why?
| | Lymphocytes | 1 | 2017 | 332 | 0.130 |
Why?
| | Graft Rejection | 1 | 2019 | 516 | 0.130 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2017 | 256 | 0.130 |
Why?
| | Anti-Infective Agents | 1 | 2018 | 225 | 0.130 |
Why?
| | Immune Evasion | 1 | 2016 | 47 | 0.130 |
Why?
| | Viral Proteins | 1 | 2017 | 281 | 0.130 |
Why?
| | Hydrogen Peroxide | 1 | 2017 | 287 | 0.130 |
Why?
| | Iron | 1 | 2017 | 233 | 0.130 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2016 | 112 | 0.130 |
Why?
| | Pyridones | 1 | 2016 | 123 | 0.130 |
Why?
| | Humans | 15 | 2019 | 114709 | 0.120 |
Why?
| | Primary Cell Culture | 1 | 2016 | 149 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2016 | 115 | 0.120 |
Why?
| | Endometriosis | 1 | 2015 | 40 | 0.120 |
Why?
| | Cryptosporidium parvum | 1 | 2014 | 10 | 0.120 |
Why?
| | Antitubercular Agents | 1 | 2016 | 169 | 0.120 |
Why?
| | Skin | 1 | 2019 | 659 | 0.120 |
Why?
| | Receptor, trkB | 1 | 2015 | 28 | 0.120 |
Why?
| | Diarrhea | 1 | 2016 | 173 | 0.120 |
Why?
| | Polymers | 1 | 2018 | 447 | 0.120 |
Why?
| | HIV Fusion Inhibitors | 1 | 2014 | 3 | 0.120 |
Why?
| | Water Pollutants, Chemical | 1 | 2017 | 175 | 0.120 |
Why?
| | Staphylococcal Infections | 1 | 2018 | 336 | 0.120 |
Why?
| | Ventricular Dysfunction | 1 | 2014 | 16 | 0.120 |
Why?
| | Extracellular Vesicles | 1 | 2015 | 83 | 0.120 |
Why?
| | Neuroprotective Agents | 1 | 2015 | 105 | 0.120 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 106 | 0.110 |
Why?
| | Microglia | 1 | 2016 | 202 | 0.110 |
Why?
| | Ventricular Function | 1 | 2014 | 56 | 0.110 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 530 | 0.110 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2013 | 128 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 928 | 0.110 |
Why?
| | Myocardial Contraction | 1 | 2015 | 312 | 0.110 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2014 | 121 | 0.110 |
Why?
| | Alleles | 1 | 2016 | 791 | 0.110 |
Why?
| | Calcium Signaling | 1 | 2015 | 213 | 0.110 |
Why?
| | Nasopharyngeal Diseases | 1 | 2012 | 5 | 0.110 |
Why?
| | Sheep Diseases | 1 | 2012 | 7 | 0.100 |
Why?
| | Bacteriophages | 1 | 2014 | 75 | 0.100 |
Why?
| | Nasal Polyps | 1 | 2012 | 49 | 0.100 |
Why?
| | Lizards | 1 | 2012 | 34 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 621 | 0.100 |
Why?
| | Cell Culture Techniques | 1 | 2013 | 343 | 0.090 |
Why?
| | Hydrogels | 1 | 2018 | 573 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2018 | 732 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 994 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1420 | 0.090 |
Why?
| | Carcinoma | 1 | 2012 | 198 | 0.090 |
Why?
| | Helicobacter Infections | 1 | 2010 | 25 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1795 | 0.090 |
Why?
| | Rodent Diseases | 1 | 2010 | 25 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2017 | 1745 | 0.090 |
Why?
| | Male | 10 | 2019 | 55554 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 396 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2014 | 708 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2012 | 263 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 811 | 0.080 |
Why?
| | Immunocompromised Host | 1 | 2010 | 195 | 0.080 |
Why?
| | Biomarkers | 2 | 2015 | 3414 | 0.080 |
Why?
| | Disease Progression | 1 | 2015 | 2384 | 0.080 |
Why?
| | Bacteria | 1 | 2014 | 726 | 0.070 |
Why?
| | Vaccination | 1 | 2016 | 1204 | 0.070 |
Why?
| | Spleen | 2 | 2019 | 484 | 0.070 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 2725 | 0.070 |
Why?
| | Chemokine CCL2 | 2 | 2019 | 105 | 0.070 |
Why?
| | Monocytes | 2 | 2019 | 503 | 0.070 |
Why?
| | Lung | 4 | 2019 | 3546 | 0.070 |
Why?
| | Swine | 2 | 2019 | 700 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2096 | 0.070 |
Why?
| | Mice | 6 | 2019 | 14916 | 0.070 |
Why?
| | Mutation | 1 | 2016 | 3349 | 0.060 |
Why?
| | Feasibility Studies | 2 | 2018 | 737 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2018 | 2582 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2019 | 1951 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2537 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2019 | 3890 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1477 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2015 | 1635 | 0.040 |
Why?
| | Chemokine CXCL10 | 1 | 2019 | 34 | 0.040 |
Why?
| | Macaca | 1 | 2019 | 50 | 0.040 |
Why?
| | Blood Cells | 1 | 2019 | 38 | 0.040 |
Why?
| | Swine, Miniature | 1 | 2019 | 71 | 0.040 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 2018 | 9 | 0.040 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2018 | 18 | 0.040 |
Why?
| | Genome, Viral | 1 | 2019 | 119 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 4710 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2019 | 225 | 0.040 |
Why?
| | Interleukin-17 | 1 | 2018 | 104 | 0.040 |
Why?
| | Duodenum | 1 | 2018 | 62 | 0.040 |
Why?
| | Dogs | 1 | 2018 | 334 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2018 | 180 | 0.040 |
Why?
| | Pyrazinamide | 1 | 2016 | 6 | 0.030 |
Why?
| | Virus Internalization | 1 | 2016 | 40 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2016 | 116 | 0.030 |
Why?
| | Isoniazid | 1 | 2016 | 52 | 0.030 |
Why?
| | Rifampin | 1 | 2016 | 68 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2016 | 241 | 0.030 |
Why?
| | Transgenes | 1 | 2016 | 170 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2017 | 511 | 0.030 |
Why?
| | Pancreas | 1 | 2018 | 277 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1040 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2016 | 155 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 812 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1449 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 545 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 741 | 0.030 |
Why?
| | Patch-Clamp Techniques | 1 | 2015 | 241 | 0.030 |
Why?
| | Receptors, CCR5 | 1 | 2014 | 54 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2016 | 295 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2014 | 79 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1370 | 0.030 |
Why?
| | Nerve Fibers | 1 | 2014 | 87 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 299 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 54 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2014 | 92 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 954 | 0.030 |
Why?
| | Cornea | 1 | 2014 | 107 | 0.030 |
Why?
| | Epidermis | 1 | 2014 | 149 | 0.030 |
Why?
| | Female | 5 | 2019 | 59483 | 0.030 |
Why?
| | Child | 1 | 2011 | 18348 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1133 | 0.030 |
Why?
| | Animals, Zoo | 1 | 2012 | 12 | 0.030 |
Why?
| | Ligands | 1 | 2014 | 564 | 0.020 |
Why?
| | Plasma | 1 | 2013 | 210 | 0.020 |
Why?
| | Thyroxine | 1 | 2012 | 58 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1226 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 354 | 0.020 |
Why?
| | Hypothyroidism | 1 | 2012 | 65 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2012 | 84 | 0.020 |
Why?
| | Hyperplasia | 1 | 2012 | 163 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 797 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 727 | 0.020 |
Why?
| | Antigens, CD | 1 | 2013 | 443 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 284 | 0.020 |
Why?
| | Omeprazole | 1 | 2010 | 5 | 0.020 |
Why?
| | Helicobacter | 1 | 2010 | 5 | 0.020 |
Why?
| | Clarithromycin | 1 | 2010 | 25 | 0.020 |
Why?
| | Amoxicillin | 1 | 2010 | 20 | 0.020 |
Why?
| | Metronidazole | 1 | 2010 | 19 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1521 | 0.020 |
Why?
| | Complement Factor D | 1 | 2010 | 27 | 0.020 |
Why?
| | Antigens, CD1 | 1 | 2010 | 57 | 0.020 |
Why?
| | Hemodynamics | 1 | 2015 | 1013 | 0.020 |
Why?
| | Sheep | 1 | 2012 | 764 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2014 | 448 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1590 | 0.020 |
Why?
| | Drug Combinations | 1 | 2010 | 286 | 0.020 |
Why?
| | Calcium | 1 | 2015 | 1103 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3004 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1134 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2321 | 0.020 |
Why?
| | Inflammation | 1 | 2017 | 2481 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 8625 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2016 | 9089 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 4521 | 0.010 |
Why?
|
|
Beck's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|